Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 21;13:1756286420947977. doi: 10.1177/1756286420947977

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2020

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Average visual acuity of the studied eyes along the plasma exchange treatment period.

The mean VA (logMAR) values of the studied eyes at the onset, 1 day before PE therapy (after IVMP treatment), after each PE cycle and at the 1-month follow-up visit were 3.4 ± 1.5, 2.6 ± 1.6, 1.9 ± 1.4, 1.8 ± 1.4, 1.8 ± 1.5, 1.7 ± 1.5, 1.7 ± 1.5 and 1.7 ± 1.5 respectively. The VA gradually improved along the treatment period (Friedman p < 0.001). The data are presented as the mean ± standard deviation.

**Adjusted p < 0.01 and ***adjusted p < 0.001, compared with the VA at onset; #adjusted p < 0.05, ##adjusted p < 0.01 and ###adjusted p < 0.001, compared with the VA before the PE therapy.

IVMP, intravenous methylprednisolone; PE, plasma exchange; VA, visual acuity.